Company Directory

Small molecule drug discovery targeting rare genetic diseases and oncology

Tay Therapeutics is a drug discovery company developing targeted small molecule therapies for rare genetic diseases and cancer. Its platform uses stop codon read-through technology to restore production of functional proteins disrupted by premature stop codon mutations, with programmes targeting oncology, cystic fibrosis, Duchenne muscular dystrophy, and epidermolysis bullosa. The company previously discovered and out-licensed two BET inhibitor programmes to VYNE Therapeutics, which are advancing in clinical trials for immuno-inflammatory conditions.

Biodiversity-derived protein data and AI models for biological design

Basecamp Research is a London-based biotech company that collects biological samples from extreme environments across more than 26 countries, building a proprietary metagenomic database of over ten billion novel protein sequences from more than one million previously unrecorded species. This dataset trains large AI foundation models for designing novel proteins and genetic medicines. The company partners with pharmaceutical, biotechnology, and industrial organisations under ethically-sourced biodiversity agreements.

Drug discovery platform targeting biomolecular condensates

Transition Bio is a biotechnology company developing a drug discovery platform based on the biology of biomolecular condensates, the membrane-less cellular structures implicated in a range of diseases. Using droplet microfluidics and machine learning, the company maps and modulates condensate behaviour to identify small-molecule candidates against targets previously considered undruggable. Lead programmes include a collaboration with Voyager Therapeutics targeting TDP-43 in ALS and frontotemporal dementia, and an internal oncology programme targeting MYC-driven cancers.

Brain-inspired AI platform for multi-target drug discovery

Symbiotic.blue is a pre-seed biotech company developing an AI-driven drug discovery platform that combines generative AI with neuroscience-inspired computational methods. The platform aims to design molecules capable of acting on multiple biological targets simultaneously, with an initial focus on obesity. The company was founded by academics from the Universities of Oxford and Cambridge alongside life sciences industry veterans.

Surface acoustic wave nebuliser platform for inhaled drug delivery

Nebu~Flow is a UK medical technology company developing next-generation nebuliser devices using patented surface acoustic wave technology to aerosolise drugs into precisely controlled droplet sizes for deep lung deposition. The platform is designed to enable inhalation delivery of biologics, RNA-based formulations, and other hard-to-nebulise drugs that currently lack viable pulmonary delivery routes. The company works with pharmaceutical partners to validate the technology ahead of regulatory submission.

Preventing cancer therapy side effects with topical medicines

VasoDynamics is a clinical-stage pharmaceutical development company focused on preventing the debilitating side effects of cancer therapy. The company develops topical formulations targeting radiation-induced oral mucositis, dermatitis, and chemotherapy-induced hair loss, using vasoconstrictor and radioprotective compounds. Its technology platform, based on IP licensed from leading UK and US research institutions, has progressed through Phase Ib and Phase IIa clinical trials. VasoDynamics serves oncology patients undergoing radiotherapy and chemotherapy.

Human iPSC platform for neurodegenerative disease drug discovery

Talisman Therapeutics is a drug discovery company specialising in human induced pluripotent stem cell (iPSC) models of neurodegenerative disease. The company operates both an internal discovery pipeline, focused on Alzheimer's disease targets including lysosome biology, pathogenic protein reduction and microglial health, and an external collaboration programme. Talisman's iPSC-derived neural cell models are designed to improve the relevance and predictivity of early-stage compound screening.

High-sensitivity lateral flow diagnostics for point-of-care testing

SwiftDx is a Cambridge-based diagnostics company developing a next generation of high-sensitivity lateral flow assays using proprietary eAMP (enhanced Amplification) and DNA detection technologies. Its platform enables detection of targets undetectable by conventional lateral flow tests, without requiring specialist equipment or laboratory facilities. The company's first commercial product is a rapid mycoplasma contamination detection kit for cell culture applications. Further products in development target HIV, dengue fever, hepatitis C, and prostate cancer.

Fibroblast immunology platform targeting cancer and inflammatory disease

Mestag Therapeutics is a clinical-stage biotechnology company developing first-in-class antibody therapies targeting activated fibroblasts to modulate immune responses in cancer and inflammatory disease. Its lead programme, MST-0312, is a bispecific antibody designed to induce tertiary lymphoid structures in solid tumours to drive anti-tumour immunity. A second programme targets a stromal inhibitory receptor to address inflammatory conditions including rheumatoid arthritis, IBD, and lupus.

Generative AI platform for TCR therapy design and immune repertoire analysis

Synteny Biotechnology is a biotechnology company developing a platform that combines high-throughput TCR-antigen data generation with generative AI to design precision T cell receptor therapies for cancer. The platform addresses a critical bottleneck in the field, namely the scarcity of paired TCR-epitope interaction data, using protein language models to engineer TCRs with improved tumour specificity and reduced cross-reactivity. The company applies this platform to an internal pipeline of TCR bispecific therapeutic candidates.

Clinical-stage CNS drug discovery using human brain genomics

Cerevance is a clinical-stage biotechnology company developing small molecule therapeutics for neurodegenerative and psychiatric disorders. The company uses its proprietary platform to profile gene expression in specific neuronal and glial cell types from a collection of over 16,000 annotated human brain tissue samples, identifying novel drug targets. Combined with machine learning analysis, this approach supports a pipeline of CNS therapeutics targeting conditions including Parkinson's disease, Alzheimer's disease and ALS.

Synthetic promoter platform for precision gene expression control

Chromatin Bioscience designs synthetic promoters and gene expression control systems for cell and gene therapy developers. Its platform uses bioinformatics to identify cell-type-selective regulatory elements from the human genome, which are assembled into novel synthetic promoters enabling precise, durable and targeted transgene expression. The company's promoters are integrated into partner programmes across oncology, nephrology and rare disease gene therapies, with a clinical-stage collaboration supporting an in vivo CAR-T candidate for multiple myeloma.